Trial Profile

Phase II Study of Fulvestrant in Combination With Abemaciclib in Hormone Receptor Positive Adenocarcinoma of Endometrium

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Fulvestrant (Primary)
Indications Adenocarcinoma; Carcinoma; Endometrial cancer
Focus Therapeutic Use

Most Recent Events

04 Jun 2024 Results (At data cutoff (October 7, 2023), n=24) assessing safety and efficacy of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
19 Jan 2024 Status changed from recruiting to active, no longer recruiting.
03 Jul 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com